Explore a selection of our essential drug information below, or:
Identification
- Brand Names
- Acam2000
- Generic Name
- Smallpox (Vaccinia) Vaccine, Live
- DrugBank Accession Number
- DB14711
- Background
The New York City Board of Health strain of Vaccinia is a viral strain used as a component of some smallpox vaccinations.1 ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain.1
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Smallpox (vaccinia) vaccine, live
- Smallpox vaccine
- Vaccinia virus live antigen, B
- Vaccinia virus strain new york city board of health live (attenuated) antigen
- Vaccinia virus strain new york city board of health live antigen
- Vaccininum
- Vaccinotoxinum
Pharmacology
- Indication
The live antigen of the New York City Board of Health strain of Vaccinia is indicated (within the ACAM2000 formulation) for active immunization against smallpox disease in patients determined to be at high risk of contracting smallpox infection.1
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prevention of Smallpox •••••••••••• •••• •••• ••• •••••••• ••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Alemtuzumab. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Acam2000 Powder, for solution 1250000 pfu / 2.5 mcL Percutaneous Emergent Product Development Gaithersburg Inc. 2024-06-20 Not applicable Canada 
Acam2000 Injection, powder, lyophilized, for solution 100000000 [PFU]/1mL Percutaneous Emergent Product Development Gaithersburg Inc. 2007-08-31 Not applicable US 
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 4SV59689SK
- CAS number
- Not Available
References
- General References
- FDA Approved Drug Products: ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) for percutaneous administration [Link]
- External Links
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data4 Completed Basic Science Smallpox Vaccine Adverse Reaction 1 somestatus stop reason just information to hide 4 Not Yet Recruiting Prevention Monkeypox 1 somestatus stop reason just information to hide 3 Completed Other Smallpox Vaccine Adverse Reaction 1 somestatus stop reason just information to hide 3 Completed Prevention 18-42 Year Old Healthy Vaccinia-naïve Subjects 1 somestatus stop reason just information to hide 3 Completed Prevention Variola Major (Smallpox) 2 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for solution Percutaneous 100000000 [PFU]/1mL Injection, powder, lyophilized, for solution Percutaneous 750000 PFU Powder, for solution Percutaneous 1250000 pfu / 2.5 mcL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created at October 02, 2018 14:34 / Updated at May 03, 2024 09:53